How much is a CVAC stock worth?
One share of CVAC stock can currently be purchased for approximately $37.35. How much money does CureVac make? CureVac has a market capitalization of $6.98 billion and generates $55.83 million in revenue each year. How many employees does CureVac have?
Where can I buy CureVac shares?
Shares of CVAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CureVac's stock price today?
What is the PE (price/book) ratio of CureVac?
CureVac has a P/B Ratio of 8.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Is CureVac a buy right now?
Should I buy or sell CureVac stock right now?
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last year. There are currently 2 sell rat...
What is CureVac's stock price forecast for 2022?
6 brokerages have issued 1-year price targets for CureVac's stock. Their forecasts range from $20.00 to $123.00. On average, they expect CureVac's...
How has CureVac's stock performed in 2022?
CureVac's stock was trading at $34.31 on January 1st, 2022. Since then, CVAC shares have decreased by 57.5% and is now trading at $14.59. View the...
Are investors shorting CureVac?
CureVac saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 5,580,000 shares, a decline of 24.4%...
When is CureVac's next earnings date?
CureVac is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022. View our earnings forecast for CureVac .
How were CureVac's earnings last quarter?
CureVac (NASDAQ:CVAC) released its quarterly earnings results on Sunday, November, 29th. The company reported ($0.24) EPS for the quarter, topping...
Who are CureVac's key executives?
CureVac's management team includes the following people: Dr. Franz-Werner Haas L.L.M. , LLD, Ph.D., LL.M., CEO & Member of Management Board (Age...
Who are some of CureVac's key competitors?
Some companies that are related to CureVac include Elanco Animal Health (ELAN) , Biohaven Pharmaceutical (BHVN) , United Therapeutics (UTHR) ,...
What other stocks do shareholders of CureVac own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA) , Tesla (TSL...
What is the ticker symbol for CureVac?
What is CureVac based on?
CureVac trades on the NASDAQ under the ticker symbol "CVAC."
Does CureVac pay dividends?
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
What is CureVac NV?
CureVac does not currently pay a dividend.
What is market cap?
CureVac NV a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in Phase 1 clinical trial for the tr
Is CV7202 a phase 1 trial?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
Does market cap include convertible securities?
eatment of four types of solid tumors, and CV7202, which it is investigating in Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2, for which the company initiated a Phase 1 clinical trial.
